August 2012
-
At its April 2020 meeting, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for Enerzair Breezhaler (QVM149) indacaterol / glycopyrronium / mometasone for the treatment of uncontrolled asthma as… Read more . . .
-
Functional respiratory imaging (FRI) company Fluidda has announced that an FRI study of COVID-19 patients has shown that the virus is resulting in narrowing of small capillaries in the lung, resulting in higher flow pressures… Read more . . .
-
Following the signing of a letter of intent for a sales agreement with Adherium, Monaghan Medical said that it will launch Adherium’s Hailie digital inhaler monitoring platform in the US. The Hailie sensor was approved… Read more . . .
-
According to Lupin, the FDA has tentatively approved the company’s arformoterol tartrate inhalation solution, a generic version of Sunovion’s Brovana, for the treatment of COPD. Sunovion’s final patent covering Brovana expires in November 2021. Brovana… Read more . . .
-
Windtree Therapeutics has announced the enrollment of the first patient in a Phase 2b bridging study of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS). In March 2020, Windtree announced that Lee Pharmaceuticals… Read more . . .
-
CDMO MedPharm announced that it has added human epithelial cell models for screening of drugs intended for the treatment of coronaviruses at its facility in Durham, North Carolina, US. The company says that use of… Read more . . .
-
Marinomed Biotech has announced new funding from the Austrian Research Promotion Agency (FFG) for development of a Carragelose inhalation solution for COVID-19 pneumonia. The funding is part of the FFG’s “Emergency Call to research COVID-19… Read more . . .
-
According to Zambon, the FDA has granted Fast Track designation to the company’s liposomal cyclosporine A for inhalation (L‑CsA‑i), which is in Phase 3 development for the treatment of bronchiolitis obliterans syndrome (BOS). Zambon acquired… Read more . . .
-
Avalyn Pharma (formerly Genoa Pharmaceuticals) announced that it has raised $35.5 million in a Series B financing round led by Norwest Venture Partners. The proceeds will fund a Phase 2/3 trial Avalyn’s AP01 nebulized pirfenidone… Read more . . .
-
Digital RDD 2020 got underway on April 26 with the announcement of the winner of the Charles G. Thiel Award for Outstanding Research and Discovery in Respiratory Drug Delivery. In a recorded presentation accessible to… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.